Democrats have introduced a bill that would allow anyone over age 50 to buy into Medicare; an FDA advisory panel has endorsed a ketamine-like depression drug; and the EPA is set to limit the amount of manmade chemicals allowed in drinking water.
On Wednesday, House and Senate Democrats introduced legislation that would allow anyone over age 50 to buy into Medicare. According to POLITICO, the bill sponsors said that the plan will pay for itself with the premiums from new enrollees and more of the money collected would pay for patient care because of “the relative lack of overhead and profit requirements in Medicare compared to the private insurance market.”
An FDA advisory panel has endorsed the experimental medication esketamine for depression. Determining that the benefits outweigh the risks, the panel voted 15-2 in favor of the ketamine-like drug. If the drug, manufactured by Johnson & Johnson, is approved, it would be the first major depression treatment approved in decades, according to STAT News. Some experts have expressed concern that the drug has a high potential for abuse because ketamine is often abused.
The EPA is expected to announce today that it will limit how much toxic chemicals from cookware and carpeting are allowed in drinking water, reported Reuters. The group of chemicals, known as PFAS, have been linked to cancer, liver and thyroid damage, and other health effects. HHS’ Agency for Toxic Substances and Disease Registry said the risk level for exposure to these chemicals should be at least 7 to 10 times lower than the threshold currently recommended by the EPA.
Facilitators of and Barriers to Medicaid Investment in Electronic Consultation Services
March 5th 2025In this qualitative investigation, leaders of Medicaid managed care plans were interviewed to identify facilitators of and barriers to electronic consultation for specialty care delivery.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Addressing Health Care Disparities Using a Health Plan Quality Measures Index
February 26th 2025The Health Insurance Disparities Index allows stakeholders to assess progress in addressing health care disparities using publicly available, validated, reported health plan quality metrics results.
Read More